Angina Pectoris
📧 Sign up to get email alerts when something new happens for Angina Pectoris.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Speed-up the Diagnosis and Evaluation of anoMalous Coronary ARTery From the Aorta [NA]
This clinical trial registry entry shows an ongoing study to speed up the diagnosis and evaluation of anomalous aortic origin of the coronar…
-
FDA approval · 2026-04-10FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for diltiazem hydrochloride from ScieGen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Angiography-Derived Physiological Indices for Outcome Prediction in Patients Undergoing OCT-Guided PCI
A clinical trial update evaluating angiography-derived physiological indices to predict outcomes in patients undergoing OCT-guided PCI, spon…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: REDUCER-I: An Observational Study of the Neovasc Reducer™ System
Clinical Trial Update indicates the REDUCER-I observational study of the Neovasc Reducer System is currently active but not recruiting. The …
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion [NA]
An update on a Nordic-Baltic randomized registry study evaluating percutaneous coronary intervention for chronic total occlusion in coronary…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon [Phase 4]
Phase 4 MIRAGE study evaluating the Mamba sirolimus-eluting PTCA balloon for coronary artery disease has completed, reporting clinical outco…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) [NA]
Clinical trial evaluating a self-expanding coronary sinus reducer for symptomatic coronary microvascular dysfunction, with status not yet re…
-
FDA approval · 2026-02-27FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original abbreviated new drug application for diltiazem hydrochloride from Macleods Pharmaceuticals Limited.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Artificial Intelligence Stress Echo (FINESSE) Project
The FINESSE AI stress echocardiography trial, sponsored by Milton Keynes University Hospital NHS Foundation Trust, is currently active but n…
-
FDA approval · 2026-02-23FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals (USA) Inc.)
The FDA approved a supplemental application for diltiazem hydrochloride from Zydus Pharmaceuticals USA Inc., approving a generic product.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
A completed clinical trial evaluating outcomes of the Xience Sierra everolimus-eluting stent in complex all-comer patients, including those …
-
FDA approval · 2026-01-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for a generic diltiazem hydrochloride product from Slate Run Pharmaceuticals, LLC under an ANDA.
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: The OCT SORT-OUT VIII Study [NA]
Aarhus University Hospital Skejby reports the OCT SORT-OUT VIII study is active but not recruiting, evaluating treatments for Coronary Arter…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Personalized Evaluation of Susptected Myocardial Ischemia [Phase 3]
Phase 3 clinical trial update for a personalized evaluation of suspected myocardial ischemia, currently enrolling by invitation in patients …
-
FDA approval · 2025-12-18FDA Approved: NICARDIPINE HYDROCHLORIDE — Supplemental Application (Chengdu Shuode Pharmaceutical Co., Ltd)
FDA approved a supplemental application for nicardipine hydrochloride by Chengdu Shuode Pharmaceutical Co., Ltd, indicating approval of a su…
-
FDA approval · 2025-12-18FDA Approved: NITROGLYCERIN — Original Application (Solaris Pharma Corporation)
FDA approved the original application (ANDA) for Nitroglycerin by Solaris Pharma Corporation, establishing a generic product indication.
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions [NA]
This clinical trial update covers the safety and potential performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in subjec…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions [NA]
This clinical trial update assesses the safety and clinical performance of the Freesolve Resorbable Magnesium Scaffold System for treating l…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System [NA]
The document notes an ongoing clinical trial evaluating the safety and clinical performance of the Freesolve resorbable magnesium scaffold s…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Invest-CTO PCI Trial [NA]
This document provides an update on the Invest-CTO PCI Trial run by Haukeland University Hospital, noting that the study is currently ACTIVE…
-
EMA approval · 2025-11-17EMA Authorised: Ivabradine Anpharm (ivabradine) — "Anpharm" Przedsiębiorstwo Farmaceutyczne S.A.
The European Medicines Agency authorised a new ivabradine product, Ivabradine Anpharm, by Anpharm Przedsiębiorstwo Farmaceutyczne S.A., for …
-
EMA approval · 2025-11-17EMA Authorised: Corlentor (ivabradine hydrochloride) — Les Laboratoires Servier
The EMA authorised Corlentor (ivabradine hydrochloride) for use in angina pectoris and heart failure. Les Laboratoires Servier is the market…
-
EMA approval · 2025-11-17EMA Authorised: Procoralan (ivabradine hydrochloride) — Les Laboratoires Servier
The European Medicines Agency has granted marketing authorization for Procoralan (ivabradine hydrochloride) for angina pectoris and heart fa…
-
FDA approval · 2025-11-14FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves the original application for diltiazem hydrochloride (Alembic Pharmaceuticals Limited), a generic product, for use in treating …
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: Clinical Evaluation of Radiation Reduction for Optimized Safety
A clinical trial to evaluate radiation reduction for safer imaging in people with coronary artery disease and myocardial infarction. The stu…